Upper Gastrointestinal Tract IrAEs: A Case Report About Sintilimab-Induced Acute Erosive Hemorrhagic Gastritis

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2022 Jun 20

PMID 35720298

Authors

Qi Ai

Wen Chen

Yonggui Li

Guoqing Li

Affiliations

Soon will be listed here.

Abstract

Introduction: Immune checkpoint inhibitors (ICIs) have now become the standard therapy for malignancies like non-small cell lung cancer and classical Hodgkin's lymphoma. ICIs are associated with unique immune-related adverse events (irAEs) caused by dysregulated immune activation. Treatment of lower gastrointestinal (GI) tract irAEs, such as colitis, is more common. However, for upper gastrointestinal tract irAEs, there is a lack of consensus in terms of globally standardized disease classification and treatment guidelines. Here, we report a case of sintilimab-induced acute erosive hemorrhagic gastritis.

Case Presentation: A 54-year-old man with metastatic NSCLC (PT2N2M1 stage IV) underwent treatment with eight courses of sintilimab + bevacizumab, followed by maintenance therapy with sintilimab alone. However, he presented with epigastric pain and melena at the end of the first sintilimab treatment, and the symptoms occurred repeatedly after regular treatment with acute erosive hemorrhagic gastritis. Repeat esophagogastroduodenoscopy (EGD) showed severe hemorrhagic gastritis; symptomatic relief and improvement in EGD images were noted for as long as he was being treated with steroids, methylprednisolone sodium.

Conclusion: As far as we are aware, we here describe the first case of sintilimab-associated acute erosive hemorrhagic gastritis, an upper gastrointestinal toxicity event. Throughout the treatment progression, differential diagnosis, multidisciplinary discussion, and the use of immunosuppressants were instrumental in clarifying the diagnosis and were crucial to the prognosis of the patient and continued treatment with ICIs.

Citing Articles

A systematic review of gastritis as an immune-related adverse event in clinical interventions.

Su F, Fan W, Zhang Y, Zhang X, Du Y, Li W Hum Vaccin Immunother. 2024; 20(1):2408852.

PMID: 39434209 PMC: 11497991. DOI: 10.1080/21645515.2024.2408852.

Analysis of complications of giant gastric ulcers induced by hepatic arterial infusion chemotherapy or combined immunotherapy: A report of three cases.

Chen S, Zhao N, Li X, Cao D Exp Ther Med. 2024; 28(5):418.

PMID: 39301251 PMC: 11411397. DOI: 10.3892/etm.2024.12707.

Cell adhesion molecules and immunotherapy in advanced non-small cell lung cancer: Current process and potential application.

Yang H, Miao Y, Yu Z, Wei M, Jiao X Front Oncol. 2023; 13:1107631.

PMID: 36895477 PMC: 9989313. DOI: 10.3389/fonc.2023.1107631.

References

Socinski M, Jotte R, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N . Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. N Engl J Med. 2018; 378(24):2288-2301. DOI: 10.1056/NEJMoa1716948. View

Yang Y, Wang Z, Fang J, Yu Q, Han B, Cang S . Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11). J Thorac Oncol. 2020; 15(10):1636-1646. DOI: 10.1016/j.jtho.2020.07.014. View

Manegold C, Dingemans A, Gray J, Nakagawa K, Nicolson M, Peters S . The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC. J Thorac Oncol. 2016; 12(2):194-207. DOI: 10.1016/j.jtho.2016.10.003. View

Patil P, Zhang X . Pathologic Manifestations of Gastrointestinal and Hepatobiliary Injury in Immune Checkpoint Inhibitor Therapy. Arch Pathol Lab Med. 2020; 145(5):571-582. DOI: 10.5858/arpa.2020-0070-RA. View

Boike J, Dejulio T . Severe Esophagitis and Gastritis from Nivolumab Therapy. ACG Case Rep J. 2017; 4:e57. PMC: 5404341. DOI: 10.14309/crj.2017.57. View

Postow M, Sidlow R, Hellmann M . Immune-Related Adverse Events Associated with Immune Checkpoint Blockade. N Engl J Med. 2018; 378(2):158-168. DOI: 10.1056/NEJMra1703481. View

Onuki T, Morita E, Sakamoto N, Nagai Y, Sata M, Hagiwara K . Severe upper gastrointestinal disorders in pembrolizumab-treated non-small cell lung cancer patient. Respirol Case Rep. 2018; 6(6):e00334. PMC: 5980602. DOI: 10.1002/rcr2.334. View

Harbour S, Maynard C, Zindl C, Schoeb T, Weaver C . Th17 cells give rise to Th1 cells that are required for the pathogenesis of colitis. Proc Natl Acad Sci U S A. 2015; 112(22):7061-6. PMC: 4460486. DOI: 10.1073/pnas.1415675112. View

Kobayashi M, Yamaguchi O, Nagata K, Nonaka K, Ryozawa S . Acute hemorrhagic gastritis after nivolumab treatment. Gastrointest Endosc. 2017; 86(5):915-916. DOI: 10.1016/j.gie.2017.04.033. View

10.

Jenks S . New therapy targets resistant non-small-cell lung cancers. J Natl Cancer Inst. 2014; 106(11). DOI: 10.1093/jnci/dju393. View

11.

Zhang Y, Zhao M, Cao S, Zhang X, Du Y . Unexpected favorable outcome to sintilimab plus bevacizumab in an EGFR-mutated non-small cell lung cancer patient: A case report. Thorac Cancer. 2020; 11(9):2717-2722. PMC: 7471034. DOI: 10.1111/1759-7714.13569. View

12.

Proto C, Ferrara R, Signorelli D, Lo Russo G, Galli G, Imbimbo M . Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): what to add and what to leave out. Cancer Treat Rev. 2019; 75:39-51. DOI: 10.1016/j.ctrv.2019.03.004. View

13.

Shi Y, Lin P, Ho E, Nock C . Nivolumab-associated nausea and vomiting as an immune adverse event. Eur J Cancer. 2017; 84:367-369. DOI: 10.1016/j.ejca.2017.07.029. View

14.

Martins F, Sofiya L, Sykiotis G, Lamine F, Maillard M, Fraga M . Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol. 2019; 16(9):563-580. DOI: 10.1038/s41571-019-0218-0. View

15.

Li Y, Wang H, Guo X, Zhou J, Duan L, Si X . [Clinical Diagnosis and Treatment of Immune-related Adverse Events in Digestive System Related to Immune Checkpoint Inhibitors]. Zhongguo Fei Ai Za Zhi. 2019; 22(10):661-665. PMC: 6817427. DOI: 10.3779/j.issn.1009-3419.2019.10.10. View

16.

Zhang M, Neyaz A, Patil D, Chen J, Dougan M, Deshpande V . Immune-related adverse events in the gastrointestinal tract: diagnostic utility of upper gastrointestinal biopsies. Histopathology. 2019; 76(2):233-243. PMC: 8386137. DOI: 10.1111/his.13963. View

17.

Tang T, Abu-Sbeih H, Luo W, Lum P, Qiao W, Bresalier R . Upper gastrointestinal symptoms and associated endoscopic and histological features in patients receiving immune checkpoint inhibitors. Scand J Gastroenterol. 2019; 54(5):538-545. DOI: 10.1080/00365521.2019.1594356. View

18.

Johncilla M, Grover S, Zhang X, Jain D, Srivastava A . Morphological spectrum of immune check-point inhibitor therapy-associated gastritis. Histopathology. 2019; 76(4):531-539. DOI: 10.1111/his.14029. View

19.

Nishimura Y, Yasuda M, Ocho K, Iwamuro M, Yamasaki O, Tanaka T . Severe Gastritis after Administration of Nivolumab and Ipilimumab. Case Rep Oncol. 2018; 11(2):549-556. PMC: 6120399. DOI: 10.1159/000491862. View

20.

Shi Y, Su H, Song Y, Jiang W, Sun X, Qian W . Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial. Lancet Haematol. 2019; 6(1):e12-e19. DOI: 10.1016/S2352-3026(18)30192-3. View